ONO Pharmaceutical Co (ON4) Financial Statements
ONO Pharmaceutical Co Financial Overview
ONO Pharmaceutical Co's market cap is currently $6.00B. The company's EPS TTM is $132.78; its P/E ratio is 14.21; and it has a dividend yield of 3.46%. ONO Pharmaceutical Co is estimated to report earnings on February 1, 2027, and the estimated EPS forecast is $0.27. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 26 | Mar 26 | Mar 25 | Mar 24 | Mar 23 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 486.87B | $ 515.78B | $ 502.67B | $ 447.19B | $ 361.36B |
| Gross Profit | $ 335.47B | $ 374.07B | $ 372.67B | $ 334.28B | $ 264.91B |
| Operating Income | $ 63.38B | $ 103.33B | $ 163.56B | $ 152.29B | $ 114.91B |
| EBITDA | $ 87.86B | $ 133.94B | $ 181.98B | $ 161.11B | $ 122.82B |
| Net Income | $ 50.05B | $ 69.77B | $ 127.98B | $ 112.72B | $ 80.52B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 210.38B | $ 237.11B | $ 204.59B | $ 164.29B | $ 116.97B |
| Total Assets | $ 1.06T | $ 1.11T | $ 913.67B | $ 882.44B | $ 739.20B |
| Total Debt | $ 146.68B | $ 120.94B | $ 8.86B | $ 9.17B | $ 8.80B |
| Net Debt | $ -57.89B | $ -116.11B | $ -157.28B | $ -86.97B | $ -60.31B |
| Total Liabilities | $ 275.84B | $ 249.87B | $ 115.06B | $ 134.62B | $ 77.53B |
| Stockholders' Equity | $ 782.45B | $ 850.73B | $ 792.96B | $ 741.87B | $ 655.91B |
| Cash Flow | |||||
| Free Cash Flow | $ 77.03B | $ 130.80B | $ 106.64B | $ 154.27B | $ 56.33B |
| Operating Cash Flow | $ 82.46B | $ 136.82B | $ 110.66B | $ 159.61B | $ 61.83B |
| Investing Cash Flow | $ -136.78B | $ -39.86B | $ 48.08B | $ -100.26B | $ 6.04B |
| Financing Cash Flow | $ 94.30B | $ -65.49B | $ -89.85B | $ -32.48B | $ -60.24B |
Currency in JPY